Literature DB >> 19958925

Lymphatic mapping helps to define resection margins for midgut carcinoids.

Yi-Zarn Wang1, Saju Joseph, Erika Lindholm, John Lyons, J Philip Boudreaux, Eugene A Woltering.   

Abstract

BACKGROUND: The extensive mesenteric lymphadenopathy associated with midgut carcinoids often causes lymphatic obstruction and leads to the development of alternative lymphatic drainage pathways. We hypothesized that altered lymphatic drainage makes traditional determination of resection margins inadequate.
METHODS: One hundred and seventy patients underwent cytoreductive surgery for neuroendocrine tumors from November 2006 to August 2008. Forty-nine patients underwent intra-operative lymphatic mapping with lymphazurin dye as a single agent. Twenty-seven patients had midgut primaries. We reviewed operative findings and pathology to evaluate the safety and efficacy of lymphatic mapping for midgut carcinoids. Lymphatic mapping defined resection margins were compared to traditional surgical margins.
RESULTS: There were no adverse events associated with the 49 lymphatic mapping procedures. Twenty-five (92%) patients had ileal and 2 had jejunal primaries. Lymphatic mapping changed traditional resection margins in 88% of patients. We preserved the ileocecal valve in 6 of 15 (40%) of patients with terminal ileal primaries.
CONCLUSION: Lymphatic mapping seems to be a safe, time efficient, and effective way to determine adequate resection margins for midgut carcinoids. We advocate using lymphatic mapping for patients with midgut carcinoids to identify adequate resection margins and assist in preservation of the ileocecal valve in patients with terminal ileal primary carcinoids.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19958925     DOI: 10.1016/j.surg.2009.09.005

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  7 in total

1.  Partial abdominal evisceration and intestinal autotransplantation to resect a mesenteric carcinoid tumor.

Authors:  William H Kitchens; Nahel Elias; Lawrence S Blaszkowsky; A Benedict Cosimi; Martin Hertl
Journal:  World J Surg Oncol       Date:  2011-01-31       Impact factor: 2.754

2.  Radioguided exploration facilitates surgical cytoreduction of neuroendocrine tumors.

Authors:  Yi-Zarn Wang; Anne Diebold; Eugene Woltering; Heather King; J Philip Boudreaux; Lowell B Anthony; Richard Campeau
Journal:  J Gastrointest Surg       Date:  2011-11-22       Impact factor: 3.452

3.  Adjuvant intraoperative post-dissectional tumor bed chemotherapy-A novel approach in treating midgut neuroendocrine tumors.

Authors:  Yi-Zarn Wang; Aman Chauhan; Michael A Hall
Journal:  J Gastrointest Oncol       Date:  2015-06

Review 4.  The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.

Authors:  James R Howe; Kenneth Cardona; Douglas L Fraker; Electron Kebebew; Brian R Untch; Yi-Zarn Wang; Calvin H Law; Eric H Liu; Michelle K Kim; Yusuf Menda; Brian G Morse; Emily K Bergsland; Jonathan R Strosberg; Eric K Nakakura; Rodney F Pommier
Journal:  Pancreas       Date:  2017-07       Impact factor: 3.327

5.  Is Multifocality an Indicator of Aggressive Behavior in Small Bowel Neuroendocrine Tumors?

Authors:  Allen B Choi; Jessica E Maxwell; Kendall J Keck; Andrew J Bellizzi; Joseph S Dillon; Thomas M OʼDorisio; James R Howe
Journal:  Pancreas       Date:  2017-10       Impact factor: 3.327

6.  Obturator Canal Lymph Node Metastasis from Rectal Carcinoid Tumors: Total Mesorectal Excision May Be Insufficient.

Authors:  Yi-Zarn Wang; David T Beyer; Michael Hall
Journal:  J Gastrointest Surg       Date:  2016-03-21       Impact factor: 3.452

7.  Does the addition of adjuvant intraoperative tumor bed chemotherapy during midgut neuroendocrine tumor debulking procedures benefit patients?

Authors:  Yi-Zarn Wang; Aman Chauhan; Robert A Ramirez; David T Beyer; Melissa A Stevens; Eugene A Woltering; J Philip Boudreaux; Lowell Anthony
Journal:  J Gastrointest Oncol       Date:  2019-10
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.